Objective Uncontrolled hypothyroidism has been associated with an increased risk of adverse pregnancy outcomes. We aimed to assess the effectiveness of increasing levothyroxine (LT4) dose on reducing the risk of adverse outcomes for pregnant women with TSH level greater than the recommended 1st trimester limit. Design, Patients, Measurements We reviewed the electronic medical records of pregnant women evaluated from January 2011 to December 2013, who had history of LT4-treated hypothyroidism and were found to have TSH > 2Á5 mIU/l in 1st trimester. Women were divided into two groups: group A -LT4 dose was increased within two weeks from the TSH test, group B -LT4 dose remained stable. We compared the frequency of pregnancy loss (primary outcome) and other prespecified pregnancy-related adverse outcomes between groups. Results There were 85 women in group A (median TSH: 5Á0, interquartile range 3Á8-6Á8 mIU/l) and 11 women in group B (median TSH: 4Á5, interquartile range 3Á2-4Á9 mIU/l). The groups were not different in baseline clinical and socioeconomic characteristics. The mean interval between TSH test and LT4 dose increase was 4Á5 (SD 4Á6) days. Pregnancy loss was significantly lower in group A (2/85, 2Á4%) vs group B (4/11, 36Á4%) (P = 0Á001). Other pregnancy-related adverse outcomes were similar between groups. Conclusions Increasing LT4 dose for women with uncontrolled hypothyroidism in the 1st trimester of pregnancy was associated with a decreased risk of pregnancy loss. Given the limitations of our study, this association awaits further confirmation from larger studies.
Introduction
Primary hypothyroidism affects 3-10% of women 1, 2 and approximately 1-2% of pregnant women receive levothyroxine (LT4) therapy during pregnancy. 3 To meet the challenge of increased metabolic needs during pregnancy, the daily thyroxine requirements could increase up to 50%. 4 These physiologic changes may result in uncontrolled hypothyroidism in women who were euthyroid with appropriate thyroid hormone replacement before pregnancy. In addition, thyroid function test results during pregnancy differ from those of nonpregnant women with TSH concentrations decreasing. Recently, in the absence of a laboratory established TSH reference range during pregnancy, a TSH of 2Á5 mIU/l has been accepted as the upper limit of normal in the 1st trimester. 5, 6 Therefore, the recommended treatment of hypothyroidism during pregnancy is with administration of oral LT4 with the goal to normalize maternal serum TSH levels (1st trimester TSH reference range 0Á1-2Á5 mIU/l). 5, 6 Overt hypothyroidism in pregnancy has consistently been shown to increase the risk of maternal and foetal complications. 7, 8 Although less frequent than overt, subclinical hypothyroidism during pregnancy has also been associated with adverse events in some studies, [8] [9] [10] but not consistently. 11, 12 Previous reports have
shown that up to 68% of pregnant women on LT4 have an elevated TSH level at their first antenatal visit. [13] [14] [15] [16] [17] [18] A recent large study found that the majority of LT4-treated women have early gestational TSH levels above the recommended targets with an increased risk of miscarriage. 19 It has been proposed that pregnant women increase the LT4 dose empirically by 30% on conception to optimize early gestation thyroid function. 3, 5, 6, 20 Our aim was to assess the effectiveness of increasing LT4 dose on reducing the risk of adverse outcomes for LT4-treated hypothyroid pregnant women with TSH level greater than the recommended at the 1st trimester.
Materials and methods

Subjects
We performed a retrospective cohort study using the electronic medical records of pregnant women between the age of 18 and 45 years, evaluated at Mayo Clinic, Rochester (Olmsted County), MN, USA, from 1 January 2011 to 31 December 2013, who had history of LT4-treated hypothyroidism and were found to have TSH > 2Á5 mIU/l in their 1st trimester. We included only women with singleton pregnancies, because with multiple pregnancies the higher HCG concentrations result in a downward shift in the TSH reference range compared to singleton pregnancies. 21 Pregnant women were excluded if free thyroxine (FT4) was checked and was found to be <0Á8 ng/dl (n = 1) or if they were using amiodarone, methimazole or propylthiouracil (n = 1). For the analysis, the cohort was subdivided into two groups: women whose LT4 dose was increased within two weeks from the TSH test (group A) and those whose LT4 dose remained stable (group B). Women who had their LT4 dose increased beyond the two weeks were excluded (n = 23). The patients were followed until pregnancy loss or hospital discharge after child delivery. This study was approved by the Institutional Review Board of Mayo Clinic, Rochester, MN, USA.
Study measures/assessments
We collected 22 23 We also collected information regarding personal history of thyroid disease, diabetes mellitus, hypertension, pregnancy loss and preterm delivery. We determined if the conception was by assisted reproduction/in vitro fertilization and if the pregnancy was followed in the Maternal Fetal Medicine clinic, which is the Obstetrics clinic for the high-risk pregnancies. At baseline, body mass index (BMI), TSH, FT4 and positivity for TPO antibody (thyroperoxidase ab) were recorded. During follow-up, information regarding pregnancy loss (miscarriage/stillbirth), preterm delivery (before 37 weeks), placental abruption, gestational diabetes, gestational hypertension, pre-eclampsia, eclampsia, premature rupture of membranes (PROM) and intrauterine growth restriction (IUGR) were collected. The birthweight and 5-min Apgar score of the neonates, admission to the neonatal intensive care unit (NICU) and duration of hospital stay after child delivery were recorded. Finally, we recorded any emergency department (ED) visits, hospital admissions and subsequent TSH testing performed during pregnancy.
Study procedures
The study cohort was identified using the laboratory data and diagnostic indices provided by Mayo Clinic. We developed a research strategy to identify women who had elevated serum TSH level during pregnancy. Based on the World Health Organization's Ninth Revision, International Classification of Diseases (ICD-9), all pregnant women at Mayo Clinic are assigned an ICD-9 code V22.nn (normal pregnancy) or V23.nn (supervision of high-risk pregnancy) at their first clinic visit. We ran a query with serum TSH > 2Á5 mIU/l AE 100 days (range) from the V22.nn or V23.nn code as well as from 632.nn (missed abortion) and 634.nn (spontaneous abortion). A detailed medical record review was subsequently conducted for all the patients identified through the queries to assess whether they satisfy the inclusion and exclusion criteria.
Assays
During the study period, serum TSH was measured using: (i) the Hybritech TSH immunoassay (Beckman Coulter DxI 800, Beckman Coulter, Inc. Brea, CA) with interassay variation of 4Á4-5Á8% and intra-assay variation of 3Á9-5Á6% and (ii) the Elecsys immunoassay (Roche Cobas 8000, Roche Diagnostics, Inc. Indianapolis, IN, USA) with interassay variation of 2Á6-10Á9% and intra-assay variation of 0Á6-1Á9%. FT4 was measured on the ADVIA Centaur platform (Siemens Diagnostics, Inc. Malvern, PA, USA) with interassay variation of 7Á4-8Á3% and intra-assay variation of 1Á9-3Á4%. TPO antibodies were measured using: (i) the Bayer anti-TPO assay on the ADVIA Centaur platform with interassay variation of 5Á1-10Á2% and intraassay variation of 1Á6-5Á2% and (ii) the Access TPO antibody immunoassay (Beckman Coulter DxI 800, Beckman Coulter, Inc. Brea, CA, USA) with interassay variation of 1Á8-14Á8% and intra-assay variation of 2Á6-6Á5%.
Data analysis
A descriptive summary analysis of patients' baseline characteristics was performed using JMP â 10.0.0 (JMP, Cary, NC, USA).
Data are presented as frequencies (percentages) for the categorical variables and means (SD; standard deviation) or median (IQR; interquartile range) as appropriate for the continuous variables. Differences between categorical variables were assessed using the chi-square test or Fisher's exact test and between continuous variables using Student's t-test (parametric) or Wilcoxon/Kruskal-Wallis test (nonparametric) as appropriate.
Outcomes of interest included: pregnancy loss (primary outcome), preterm delivery, placental abruption, gestational diabetes, gestational hypertension, pre-eclampsia, eclampsia, PROM, IUGR, low birthweight (LBW; <2500 g), low 5-min Apgar score (≤7), NICU admission, neonatal death (restricted to the immediate postpartum period until mother's hospital discharge) and duration of hospital stay. A P-value of <0Á05 was considered to be statistically significant, and all testing was two-sided.
Results
Baseline characteristics of subjects
During the study period, 96 pregnant women were identified with history of hypothyroidism on LT4 replacement and a TSH > 2Á5 mIU/l in their 1st trimester of pregnancy. For 85 women with a median TSH 5 mIU/l (IQR 3Á8-6Á8 mIU/l), LT4 dose was increased (group A) compared to 11 women with median TSH 4Á5 mIU/l (IQR 3Á2-4Á9 mIU/l) whose LT4 dose remained stable (group B). The mean gestational age at the time of TSH testing was 7Á2 (SD 2Á3) weeks for group A and 6Á8 (SD 2Á7) weeks for group B (P = 0Á59). The mean interval between TSH test and LT4 dose increase was 4Á5 (SD 4Á6) days. Group A had an initial mean LT4 dose of 129Á4 (SD 43Á8) mcg which was subsequently increased on average 27Á5% (SD 11Á4%). The mean LT4 dose for group B was 90Á8 (SD 30Á0) mcg. The distribution of different types of thyroid disease between the two groups is described in Table 1 . Baseline characteristics were no different between groups (Table 2) . No pregnant woman reported illicit drug use. Four patients had history of type 1 diabetes and one patient had history of hypertension, all in group A. Nine pregnancies (11%) were conceived by assisted reproduction/in vitro in group A compared to none in group B (P = 0Á59). Finally, similar number of patients was followed in the Maternal Fetal Medicine clinic (group A; n = 2, 2Á4%, group B; n = 0, 0%, P = 0Á99). Table 3 describes the adverse outcomes between the two groups. Pregnancy loss was significantly lower in group A (2/85, 2Á4%) vs group B (4/11, 36Á4%) (P = 0Á001). Table 4 describes the cases of pregnancy loss. There was no reported cause of the pregnancy losses in the medical records. Only one patient from group A had a repeated TSH testing prior to the pregnancy loss which was at goal (2Á1 mIU/l). None of the patients in group B had a repeated TSH testing prior to the pregnancy loss. We performed a sensitivity analysis by excluding the two cases from group B that pregnancy loss occurred within one week from the TSH testing as any LT4 dose change would have been unlikely to have impact on the outcome. Pregnancy loss remained significantly lower in group A (2/85, 2Á4%) vs group B (2/9, 22Á2%) (P = 0Á04).
Pregnancy important outcomes and follow-up
There was no significant difference between the two groups in the frequency of preterm delivery, gestational diabetes, gestational hypertension, pre-eclampsia, placenta previa, placenta abruption, LBW or Apgar ≤7 at 5 min. Thirteen women in group A (15Á3%) had PROM compared to none in group B (P = 0Á35). No pregnant woman developed eclampsia or had IUGR. There were no events of congenital malformations or neonatal death. The mean duration of the hospital stay was 2Á6 (SD 1Á0) days for group A, similar with group B at 3Á0 (SD 1Á2) days (P = 0Á36).
After initiating LT4, 35 pregnant women in group A had a repeat TSH testing while there were still in the 1st trimester with 17 women having achieved TSH at goal (17/35, 49%). By the second trimester, 93% of pregnant women in group A had a (14) 1 (9) LT4, Levothyroxine therapy. *Nine patients were treated with radioactive iodine, two patients had thyroidectomy, and one patient had no documentation of the definitive treatment. 
LT4, Levothyroxine therapy; BMI, body mass index; TSH, thyroid stimulating hormone; TPO-ab, thyroperoxidase antibody; Hx, history; college+, at least some college or two-year degree. *Available in 68% of the cohort. **Group A, n = 55 and Group B, n = 8.
TSH at goal. Two women achieved TSH at goal only in the 3rd trimester; one of them had PROM. Finally, three women never achieved TSH at goal; one of them had PROM and subsequent preterm delivery. The median percentage of trimester-specific TSH level at goal was 75% (IQR 62-100%). The median TSH level was 1Á3 mIU/l (IQR 0Á8-2Á1 mIU/l) at the last testing before the end of pregnancy. From the seven remaining pregnant women in group B, five had spontaneously a TSH level at goal at the second testing (2/5 were still in the 1st trimester and 3/5 were in the 2nd trimester) and two at the third testing during pregnancy (both women in the 2nd trimester); therefore, LT4 dose remained stable. The median TSH level was 2Á4 mIU/l (IQR 2Á2-2Á8 mIU/l) at the last testing before the end of pregnancy.
One patient from group A was recorded to have palpitations; however, her TSH level was at goal. There was no difference between groups regarding the number of ED visits or hospital admissions during pregnancy (data not shown). A Caesarian delivery was performed for 30/84 (36%) of women in group A and 4/7 (57%) in group B. Complete follow-up was available for all patients.
Discussion
In this single-centre study, 96 LT4-treated pregnant women with uncontrolled hypothyroidism in their 1st trimester of pregnancy were identified. An association of increasing LT4 dose with decreased risk of pregnancy loss was found; however, there was no apparent effect on other important adverse maternal or foetal outcomes. This suggests that once the critical stage of the 1st trimester of pregnancy has been completed, the chances of an uncomplicated pregnancy would be appreciable for issues associated with hypothyroidism. It has been previously described that LT4 requirements plateau by week 16 of gestation. 3 This may contribute to the success of the patients who had a stable LT4 dose in achieving eventually TSH normalization and having similar risk for late-pregnancy complications with the patients who had their LT4 dose increased at the beginning of pregnancy. A recent population-based study 19 showed that among 1013 LT4-treated women, 63% had in their 1st trimester a TSH level above the recommended goal of 2Á5 mIU/l. Compared to LT4-treated women with TSH levels within the current guidelines (0Á2-2Á5 mIU/l), women with TSH > 2Á5 mIU/l in the 1st trimester had an increased risk of miscarriage after adjusting for age, year of pregnancy, diabetes and socioeconomic characteristics. The risk of miscarriage was increased in women with TSH 4Á51-10 mIU/l [odds ratio (OR) 1Á80, 95% confidence interval (CI) 1Á03, 3Á14)] and TSH > 10 mIU/l (OR 3Á95, 95% CI 1Á87, 8Á37). Similarly, Abalovich et al. 24 showed that when treatment with levothyroxine was inadequate, pregnancy loss occurred in 60% of overtly hypothyroid patients and in 71Á4% of patients with subclinical hypothyroidism, whereas when treatment was adequate, 100% of overtly hypothyroid patients and 90Á5% of patients with subclinical hypothyroidism carried the pregnancies to term. Hallengren et al. 15 found that foetal loss was Neonatal outcomes, n (%)
LT4, Levothyroxine; NICU, neonatal intensive care unit. significantly greater in pregnant women with TSH value above 4Á0 mIU/l (5/19, 26%) compared to those with normal TSH values (2/32, 6%). From a biologic standpoint, these findings are supported by human studies suggesting that adequate thyroid hormonal availability is important at the level of placental trophoblasts. 25 Therefore, inadequate treatment may have caused the pregnancy losses for the women in group B and possibly for the one woman in group A as there was no documentation of TSH normalization after her levothyroxine dose was increased. This body of evidence underlines the need for a strict and early follow-up in pregnancy of women with treated hypothyroidism. Close treatment monitoring will allow detecting the need for increases in the LT4 dose in most patients during pregnancy. Although no prospective, randomized investigation of LT4 intervention has occurred in hypothyroid pregnant women, such an investigation would be unethical and prohibitive to complete. Despite the small sample size, our study is the largest to date reporting on adverse pregnancy outcomes of women with LT4-treated uncontrolled hypothyroidism that LT4 dose was increased compared to those that was not, allowing us to show the effectiveness of increasing LT4 dose in the 1st trimester on reducing the risk of pregnancy loss. This finding supports the current clinical practice guidelines that recommend LT4-treated hypothyroid patients who are newly pregnant should independently increase their dose of LT4 by approximately 25-30% upon a missed menstrual cycle or positive home pregnancy test and notify their caregiver promptly. 5 However, this increase might be insufficient, as it has been observed in the study by Verga et al. 26 where patients needed to increase their LT4 dose from 45% to 70%. Therefore, it has been suggested that to best achieve normal TSH levels early, during the 1st trimester, the thyroid status on LT4 needs to be optimized even before the patient becomes pregnant. 27 The main limitation of our study is its retrospective design, which results in no randomization of the patients to balance their prognosis. In addition, there is also a risk of selection bias due to physicians being more likely to intensify the treatment for patients considered at higher risk for complications; this bias, however, would strengthen the findings of benefit. This is a single-centre study including mostly Caucasian, well-educated pregnant women; therefore, the results may not be applicable to the general population. Although the presence of referral bias cannot be excluded, the number of pregnant women followed in the Maternal Fetal Medicine clinic suggesting a high-risk pregnancy was small and similar between the two groups. In addition, there may be some nonapparent clinical differences in the aetiology of the pregnancy loss. Finally, many of the secondary adverse pregnancy outcomes are uncommon and differences between groups may not have been possible to detect due to our sample size. The low number of women and events also affects the main analysis, likely underestimating the P-value associated with the observed differences. Although it would have been clinically meaningful, we were not able to perform analysis based on a TSH cut-off level due to the small size of those subgroups. However, an important strength of our study is the use of electronic medical records capturing detailed clinical data which in combination with the fact that we had complete follow-up of our subjects allowed us to have a complete outcome assessment. Finally, we had data on multiple potential confounders, most notably socioeconomic measures and obstetric comorbid conditions.
In conclusion, increasing LT4 dose to improve the adequacy of thyroid hormone replacement for uncontrolled hypothyroidism during pregnancy was associated with a decreased risk of pregnancy loss. Given the limitations of our study, this association awaits confirmation in larger studies that will also establish the optimal TSH target during pregnancy.
